Evidence map›Paper›PMID 36158586›Full record

ArticleLiver cancer2022

Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.

Masafumi Ikeda, Yasuaki Arai, Yoshitaka Inaba, Toshihiro Tanaka, Shunsuke Sugawara, Yoshihisa Kodama, Takeshi Aramaki, Hiroshi Anai, Shinichi Morita, Yoshinori Tsukahara and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Radiomic Analysis Applied to Pretreatment Gd-EOB-DTPA-enhanced MR Imaging Predicts Response to Selective Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Masafumi IkedaDepartment of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yasuaki AraiExecutive Advisor to the President, National Cancer Center, Tokyo, Japan.
Yoshitaka InabaDepartment of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
Toshihiro TanakaDepartment of Radiology, IVR Center, Nara Medical University, Kashihara, Japan.
Shunsuke SugawaraDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Yoshihisa KodamaDepartment of Radiology, Teine Keijinkai Hospital, Sapporo, Japan.
Takeshi AramakiDivision of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroshi AnaiDepartment of Radiology, Nara City Hospital, Nara, Japan.
Shinichi MoritaDepartment of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Hospital, Minamiuonuma, Japan.
Yoshinori TsukaharaDepartment of Radiology, Shinshu University School of Medicine, Matsumoto, Japan.
Hiroshi SekiDepartment of Diagnostic Radiology, Niigata Cancer Center Hospital, Niigata, Japan.
Mikio SatoDepartment of Gastroenterology and Hepatology, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Kenya KamimuraDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Kimei AzamaDepartment of Radiology, Ryukyu University Hospital, Nishihara, Japan.
Masakatsu TsurusakiDepartment of Radiology, Kindai University Faculty of Medicine, Osaka-sayama, Japan.
Eiji SugiharaDepartment of Diagnostic Imaging, Osaka General Medical Center, Osaka, Japan.
Masaya MiyazakiDepartment of Applied Medical Imaging, Gunma University Graduate School of Medicine, Maebashi, Japan.
Tatsushi KobayashiDepartment of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan.
Miyuki SoneDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: With the advent of effective systemic therapy, transarterial chemoembolization (TACE) is established as a highly effective locoregional treatment modality for carefully selected patients with hepatocellular carcinoma (HCC). This randomized controlled trial was conducted to clarify whether selective TACE with drug-eluting beads (DEB-TACE) loaded with epirubicin or selective conventional TACE (cTACE) with epirubicin-ethiodized oil might be more effective for obtaining complete response(CR) in patients with HCC. Methods: Between March 2016 and May 2019, Child-Pugh class A or B patients with unresectable HCC who were scheduled to receive selective TACE were randomly assigned at a 1:1 ratio to the DEB-TACE arm or the cTACE arm. The primary endpoint was the CR rate at 3 months, as evaluated according to the modified Response Evaluation Criteria in Solid Tumors by an independent review committee, and the secondary endpoints were the CR rate at 1 month and incidences of adverse events. Results: A total of 200 patients (DEB-TACE, 99 patients; cTACE, 101 patients) were enrolled in the study. The CR rates at 3 months and 1 month were significantly higher in the cTACE arm (75.2%, 84.2%) as compared with the DEB-TACE arm (27.6%, 35.7%). However, the frequencies of adverse events of any grade, including pyrexia (DEB-TACE vs. cTACE, 19.4% vs. 45.5%, Conclusions: Selective cTACE appeared to have higher CR rates for local tumor control as compared to selective DEB-TACE for HCC. However, the frequency of postembolization syndrome was also significantly higher in the cTACE group than in the DEB-TACE group. Thus, to achieve CR, cTACE may be selected over DEB-TACE in patients who can be expected to tolerate postembolization syndrome.

Indexed as

Drug-eluting beadsEpirubicinEthiodized oilHepatocellular carcinomaTransarterial chemoembolization

Identifiers

PMID36158586
PMCPMC9485929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.